Page 82 - 《中国药房》2020年23期

1071-1078. （1）：37-44.
[ 7 ] HE T. Systematic review：cost-effectiveness of direct-ac- [19] ROLLI FR. Economic evaluation of zepatier for the man-
ting antivirals for treatment of hepatitis C genotypes agement of HCV in the Italian scenario[J]. Eur J Health
2-6[J]. Aliment Pharmacol Ther，2017，46（8）：711-721. Econ，2018，19（9）：1365-1374.
[ 8 ] CASTRO R. Cost-effectiveness of diagnostic and thera- [20] RUGGERI M. Cost-effectiveness analysis of daclatasvir/
peutic interventions for chronic hepatitis C：a systematic sofosbuvir for the treatment of the HCV patients failed af-
review of model-based analyses[J]. BMC Med Res Me- ter the first line with second generation of DAAs in Ita-
thodol，2018，18（1）：53-65. ly[J]. Expert Rev Pharmacoecon Outcomes Res，2019，19
[ 9 ] HUSEREAU D，DRUMMOND M，PETROU S，et al. （3）：363-374.
Consolidated Health Economic Evaluation Reporting Stan- [21] SAINT-LAURENT TC. Cost-effectiveness of combina-
dards（CHEERS）：explanation and elaboration：a report tion daclatasvir-sofosbuvir for treatment of genotype 3
of the ISPOR health economic evaluations publication chronic hepatitis C infection in the United States[J]. J
guidelines task force[J]. Value Health，2013，16（2）：231- Med Econ，2017，20（7）：692-702.
250. [22] VIRABHAK S. Cost-effectiveness of direct-acting antivi-
[10] HUSEREAU D，DRUMMOND M，PETROU S，et al. ral regimen ombitasvir/paritaprevir/ritonavir in treat-
Consolidated Health Economic Evaluation Reporting Stan- ment-naive and treatment-experienced patients infected
dards（CHEERS）statement[J]. Int J Tech Assess Health with chronic hepatitis C virus genotype 1b in Japan[J]. J
Care，2013，29（2）：117-122. Med Econ，2016，19（12）：1144-1156.
[11] 李超，李娜，董淑杰.达比加群酯在心房颤动患者抗凝治 [23] WARD T. Assessing the budget impact and economic out-
疗的药物经济学系统评价[J].药品评价，2018，15（10）： comes of the introduction of daclatasvir + asunaprevir and
23-27. sofosbuvir/ledipasvir for the treatment of chronic hepatitis
[12] CHEN P，MA A，LIU Q，et al. Cost-effectiveness of elbas- C virus infection in Japan[J]. Value Health Reg Issues，
vir/grazoprevir versus daclatasvir plus asunaprevir in pa- 2017. DOI：10.1016/j.vhri.2016.10.002.
tients with chronic hepatitis C virus genotype 1b infection [24] 陈平钰，谢青.艾尔巴韦格拉瑞韦与索磷布韦维帕他韦治
in China[J]. Clin Drug Investig，2018，38（11）：1031- 疗丙型肝炎的成本-效果分析[J].中国药物经济学，2019，
1039. 14（7）：14-18、26.
[13] CORMAN S. Cost-utility of elbasvir/grazoprevir in pa- [25] 杨馥宁，贺小宁，吴晶.基于Markov模型对新型抗病毒药
tients with chronic hepatitis C genotype 1 infection[J]. 物治疗基因 1b 型慢性丙型肝炎的药物经济学评价[J].
Value in Health，2017，20（8）：1110-1120. 中国药学杂志，2019，54（15）：1276-1284.
[14] ELSISI GH，ABURAWASH A，WAKED E，et al. Cost-ef- [26] CHHATWAL J，HE T，LOPEZ-OLIVO MA，et al. Syste-
fectiveness analysis of new HCV treatments in Egyptian matic review of modelling approaches for the cost effec-
cirrhotic and non-cirrhotic patients：a societal perspec- tiveness of hepatitis C treatment with direct-acting antivi-
tive[J]. Value Health Reg Issues，2017，13（7）：7-15. rals[J]. Pharmaco Economics，2016，34（6）：551-567.
[15] KAWAGUCHI I. A cost-effectiveness analysis of glecapre- [27] CHHATWAL J，CHEN Q，AGGARWAL R，et al. Estima-
vir/pibrentasvir versus existing direct-acting antivirals to tion of hepatitis C disease burden and budget impact of
treat chronic hepatitis C in Japan[J]. Advances in Therapy， treatment using health economic modeling[J]. Infect Dis
2020，37（1）：457-476. Clin N Am，2018，32（2）：461-480.
[16] MATTINGLY TN，SLEJKO JF，MULLINS CD，et al. He- [28] LUHNEN M. Health economic evaluations of sofosbuvir
patitis C treatment regimens are cost-effective：but com- for treatment of chronic hepatitis C：a systematic re-
pared with what?[J]. Ann Pharmacother，2017，51（11）： view[J]. Appl Health Econ Health Policy，2016. DOI：10.
961-969. 1007/s40258-016-0253-2.
[17] MCEWAN P. Estimating the cost-effectiveness of daclatas- [29] MEIJERINK H，WHITE RA，LVLIE A，et al. Modelling
vir + sofosbuvir versus sofosbuvir + ribavirin for patients the burden of hepatitis C infection among people who in-
with genotype 3 hepatitis C virus[J]. Cost Eff Resour Al- ject drugs in Norway，1973-2030[J]. BMC Infec Dis，
loc，2017. DOI：10.1186/s12962-017-0077-4. 2017，17（1）：541-567.
[18] RESTELLI U. Cost-effectiveness analysis of the use of da- [30] 赵可新.模型研究方法在药物经济学中的应用概述[J].
clatasvir+sofosbuvir+ribavirin（16 weeks and 12 weeks） 中国药师，2015，18（9）：1561-1564.
vs sofosbuvir+ribavirin（16 weeks and 24 weeks）for the （收稿日期：2020-04-29 修回日期：2020-07-12）
treatment of cirrhotic patients affected with hepatitis C vi- （编辑：刘明伟）
rus genotype 3 in Italy[J]. Eur J Health Econ，2018，19

·2888 · China Pharmacy 2020 Vol. 31 No. 23 中国药房 2020年第31卷第23期